Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia.

Literature DB >> 26674111

A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia.

Lukas D Wartman¹, Mark A Fiala¹, Theresa Fletcher¹, Emily R Hawkins¹, Amanda Cashen¹, John F DiPersio¹, Meagan A Jacoby¹, Keith E Stockerl-Goldstein¹, Iskra Pusic¹, Geoffrey L Uy¹, Peter Westervelt¹, Ravi Vij¹.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2015 PMID： 26674111 PMCID： PMC4888765 DOI： 10.3109/10428194.2015.1076930

Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022

× No keyword cloud information.

14 in total

1. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

Authors: Susan D Demo; Christopher J Kirk; Monette A Aujay; Tonia J Buchholz; Maya Dajee; Mark N Ho; Jing Jiang; Guy J Laidig; Evan R Lewis; Francesco Parlati; Kevin D Shenk; Mark S Smyth; Congcong M Sun; Marcy K Vallone; Tina M Woo; Christopher J Molineaux; Mark K Bennett
Journal: Cancer Res Date: 2007-07-01 Impact factor: 12.701

2. Effective targeting of primitive AML CD34+ cells by the second-generation proteasome inhibitor carfilzomib.

Authors: Lieke H van der Helm; Matthieu C J Bosman; Jan J Schuringa; Edo Vellenga
Journal: Br J Haematol Date: 2015-04-14 Impact factor: 6.998

Review 3. Proteasome inhibitors in acute leukemia.

Authors: Denise Niewerth; Ilse Dingjan; Jacqueline Cloos; Gerrit Jansen; Gertjan Kaspers
Journal: Expert Rev Anticancer Ther Date: 2013-03 Impact factor: 4.512

Review 4. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.

Authors: Andrzej J Jakubowiak
Journal: Cancer Treat Rev Date: 2014-03-01 Impact factor: 12.111

5. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.

Authors: Terzah M Horton; Debananda Pati; Sharon E Plon; Patrick A Thompson; Lisa R Bomgaars; Peter C Adamson; Ashish M Ingle; John Wright; Adam H Brockman; Martin Paton; Susan M Blaney
Journal: Clin Cancer Res Date: 2007-03-01 Impact factor: 12.531

6. Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.

Authors: Han Liu; Todd D Westergard; Amanda Cashen; David R Piwnica-Worms; Lori Kunkle; Ravi Vij; Can G Pham; John DiPersio; Emily H Cheng; James J Hsieh
Journal: Cancer Cell Date: 2014-04-14 Impact factor: 31.743

7. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.

Authors: Eyal C Attar; Daniel J De Angelo; Jeffrey G Supko; Ferdinando D'Amato; David Zahrieh; Andres Sirulnik; Martha Wadleigh; Karen K Ballen; Steve McAfee; Kenneth B Miller; James Levine; Ilene Galinsky; Elizabeth G Trehu; David Schenkein; Donna Neuberg; Richard M Stone; Philip C Amrein
Journal: Clin Cancer Res Date: 2008-03-01 Impact factor: 12.531

8. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.

Authors: Camilla Stapnes; Anne P Døskeland; Kimberley Hatfield; Elisabeth Ersvaer; Anita Ryningen; James B Lorens; Bjørn Tore Gjertsen; Oystein Bruserud
Journal: Br J Haematol Date: 2007-03 Impact factor: 6.998

Review 9. Targeted treatments for multiple myeloma: specific role of carfilzomib.

Authors: Dhivya Sugumar; Jesse Keller; Ravi Vij
Journal: Pharmgenomics Pers Med Date: 2015-01-20

10. Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy.

Authors: Chiara Sarlo; Francesco Buccisano; Luca Maurillo; Mariagiovanna Cefalo; Luigi Di Caprio; Laura Cicconi; Concetta Ditto; Licia Ottaviani; Ambra Di Veroli; Maria Ilaria Del Principe; Maria Assunta Grasso; Daniela Nasso; Giovanna De Santis; Sergio Amadori; Adriano Venditti
Journal: Leuk Res Treatment Date: 2013-04-28

11 in total

Review 1. [Advances in targeted therapy for childhood acute myeloid leukemia].

Authors: Ni-Na Wang; Qi-Dong Ye
Journal: Zhongguo Dang Dai Er Ke Za Zhi Date: 2017-07

2. Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.

Authors: Tyler W Jenkins; Sondra L Downey-Kopyscinski; Jennifer L Fields; Gilbert J Rahme; William C Colley; Mark A Israel; Andrey V Maksimenko; Steven N Fiering; Alexei F Kisselev
Journal: Sci Rep Date: 2021-05-25 Impact factor: 4.379

Review 3. The Ubiquitin-Proteasome System in Immune Cells.

Authors: Gonca Çetin; Sandro Klafack; Maja Studencka-Turski; Elke Krüger; Frédéric Ebstein
Journal: Biomolecules Date: 2021-01-05

Review 4. The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia.

Authors: Chun-Fung Sin; Pui-Hei Marcus Man
Journal: Front Oncol Date: 2021-12-23 Impact factor: 6.244

5. Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors.

Authors: Andrej Besse; Marianne Kraus; Max Mendez-Lopez; Elmer Maurits; Herman S Overkleeft; Christoph Driessen; Lenka Besse
Journal: Cells Date: 2022-03-01 Impact factor: 6.600

6. A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation.

Authors: Min Yang; Zengkai Pan; Kezhi Huang; Guntram Büsche; Hongyun Liu; Gudrun Göhring; Regina Rumpel; Oliver Dittrich-Breiholz; Steven Talbot; Michaela Scherr; Anuhar Chaturvedi; Matthias Eder; Julia Skokowa; Jianfeng Zhou; Karl Welte; Nils von Neuhoff; Ligen Liu; Arnold Ganser; Zhixiong Li
Journal: Leukemia Date: 2021-11-03 Impact factor: 11.528